A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma
- PMID: 39810544
- PMCID: PMC11845103
- DOI: 10.1080/14796694.2024.2442851
A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma
Plain language summary
What is this summary about?This summary presents the 7-year study results from COLUMBUS part 1, which tested encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) combined (COMBO group) against encorafenib alone (ENCO group) or vemurafenib (ZELBORAF®) alone (VEMU group) as a treatment for a skin cancer called locally advanced or metastatic BRAF V600-mutant melanoma.What were the results?More participants in the COMBO group were alive for longer and without their disease getting worse after 7 years than those in the VEMU group.Among participants who switched to a new anticancer treatment, those in the COMBO group lived longer than those in the VEMU or ENCO groups.What do the results of the study mean?This confirms that people with BRAF V600-mutant melanoma treated with encorafenib plus binimetinib or encorafenib alone lived longer than those treated with vemurafenib.[Box: see text].
Conflict of interest statement
Dirk Schadendorf. Honoraria: Roche/Genentech, Novartis, Bristol Myers Squibb, MSD, Immunocore, Merck Serono, Array BioPharma, Pfizer, Pierre Fabre, Philogen,Regeneron, 4SC, Sanofi/Regeneron, NeraCare GmbH, Sun Pharma, Inflarx GmbH, Ultimovacs, Sandoz, Amgen, Daiichi Sankyo Japan, LabCorp, Nektar, Replimune.Consulting or Advisory Role: Roche/Genentech, Novartis, Bristol Myers Squibb, MSD, Merck Serono, 4SC, Pierre Fabre, Sanofi/Regeneron, Nektar. Speakers’ Bureau:Bristol Myers Squibb, MSD, Novartis, Pierre Fabre, Sanofi/Regeneron, Merck KGaA. Research Funding: Bristol Myers Squibb (Inst), Novartis (Inst), Roche (Inst), MSD Oncology (Inst), Array BioPharma/Pfizer (Inst), Amgen (Inst). Travel, Accommodations, Expenses: Roche/Genentech, Bristol Myers Squibb, Merck Serono, Novartis,MSD, Pierre Fabre, Sanofi/Regeneron.
Reinhard Dummer. Honoraria: Roche, Novartis, Bristol Myers Squibb, MSD, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, CatalYm, Second Genome, Regeneron,Alligator Bioscience, MaxiVAX, touchIME, T3 Pharmaceuticals, Pfizer. Consulting or Advisory Role: Roche, Bristol Myers Squibb, MSD, Novartis, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, CatalYm, Second Genome, Alligator Bioscience, touchIME, MaxiVAX, Regeneron, Pfizer, T3 Pharmaceuticals. Research Funding: Roche (Inst), Bristol Myers Squibb (Inst), Novartis (Inst), MSD (Inst), Amgen (Inst).
Keith T. Flaherty. Stock and Other Ownership Interests: Clovis Oncology, Loxo, X4 Pharma, Strata Oncology, PIC Therapeutics, Apricity Health, Oncoceutics,FogPharma, Tvardi Therapeutics, Checkmate Pharmaceuticals, Kinnate Biopharma, Scorpion Therapeutics, ALX Oncology, xCures, Monopteros Therapeutics,Vibliome Therapeutics, Transcode Therapeutics, Soley Therapeutics, Nextech Invest. Consulting or Advisory Role: Novartis, Lilly, Oncoceutics, Tvardi Therapeutics,Takeda, Debiopharm Group.
Caroline Robert. Stock and Other Ownership Interests: Ribonexus. Consulting or Advisory Role: Bristol Myers Squibb, Roche, Novartis, Pierre Fabre, MSD, Sanofi,AstraZeneca, Pfizer. Research Funding: Novartis (Inst).
Ana Arance. Consulting or Advisory Role: Bristol Myers Squibb, Roche, Novartis, Pierre Fabre, MSD, Merck, Sanofi. Speakers’ Bureau: Pierre Fabre, Novartis, MSD,Bristol Myers Squibb, Roche, Merck, Sanofi Research Funding: Pierre Fabre (Inst), Novartis (Inst), Roche (Inst), Bristol Myers Squibb (Inst), MSD (Inst), Merck (Inst),Sanofi (Inst). Travel, Accommodations, Expenses: Bristol Myers Squibb, MSD, Novartis, Pierre Fabre.
Jan Willem B. de Groot. Consulting or Advisory Role: Bristol Myers Squibb, Pierre Fabre, Servier.
Claus Garbe. Honoraria: CeCaVa, MSD Oncology, NeraCare GmbH, Philogen. Consulting or Advisory Role: CeCaVa, MSD Oncology, NeraCare GmbH, Philogen.
Helen J. Gogas. Consulting or Advisory Role: Bristol Myers Squibb, MSD, Pierre Fabre, Sanofi. Speakers’ Bureau: Bristol Myers Squibb, MSD, Novartis, Pierre Fabre,Sanofi.Steering Committee Member: Amgen, Replimune. Research Funding: Amgen (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Iovance (Inst), Lilly (Inst), MSD (Inst), Pfizer (Inst), Pierre Fabre (Inst).
Ralf Gutzmer. Honoraria: Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Merck Serono, Almirall Hermal GmbH, Amgen, Sun Pharma, Pierre Fabre, Sanofi/Regeneron, Immunocore. Consulting or Advisory Role: Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Almirall Hermal GmbH, 4SC, Amgen, Pierre Fabre Merck Serono, Sun Pharma,Sanofi/Regeneron, Immunocore, Delcath. Research Funding: Amgen (Inst), Merck Serono (Inst), Sun Pharma (Inst), Sanofi/Regeneron (Inst),Kyowa Kirin (Inst), Almirall Hermal GmbH (Inst). Travel, Accommodations, Expenses: Pierre Fabre, Sun Pharma, Boehringer Ingelheim.
Ivana Krajsová. No disclosures or conflicts of interest to report.
Gabriella Liszkay. Consulting or Advisory Role: Roche, MSD, Novartis, Bristol Myers Squibb/Pfizer, Sanofi, Pfizer. Speakers’ Bureau: Bristol Myers Squibb, MSD Oncology (Inst), Sanofi. Research Funding: Roche, Novartis (Inst), Incyte Corporation (Inst).
Carmen Loquai. Consulting or Advisory Role: Bristol Myers Squibb (Inst), MSD (Inst), BioNTech (Inst), Novartis (Inst), Sanofi (Inst), Pierre Fabre (Inst), Almirall Hermal GmbH (Inst), Sun Pharma (Inst), Merck (Inst), Roche (Inst), Kyowa Kirin International (Inst). Travel, Accommodations, Expenses: Bristol Myers Squibb (Inst), MSD (Inst),BioNTech (Inst), Novartis (Inst), Sanofi (Inst), Pierre Fabre (Inst), Almirall Hermal GmbH (Inst), Sun Pharma (Inst), Merck (Inst), Roche (Inst), Kyowa Kirin International (Inst).
Mario Mandalà. Honoraria: MSD Oncology, Novartis, Pierre Fabre, Sanofi/Aventis, Bristol Myers Squibb/Sanofi. Consulting or Advisory Role: Bristol Myers Squibb, MSD Oncology, Novartis, Pierre Fabre. Research Funding: Novartis (Inst).
Naoya Yamazaki. Consulting or Advisory Role: Ono Pharmaceutical, Chugai Pharma, MSD. Speakers’ Bureau: Ono Pharmaceutical, Bristol Myers Squibb Japan, Novartis, MSD. Research Funding: Ono Pharmaceutical (Inst), Bristol Myers Squibb Japan (Inst), Novartis (Inst), Astellas Amgen BioPharma (Inst), Merck Serono (Inst), Takara Bio (Inst).
Paola Queirolo. Consulting or Advisory Role: Pierre Fabre, Roche, Novartis, MSD, Bristol Myers Squibb, Sun Pharma, Sanofi/Regeneron, Merck Serono.
Carolin Guenzel. Stock and Other Ownership Interests: Pfizer. Honoraria: Pfizer.
Anna Polli. Stock and Other Ownership Interests: Pfizer. Honoraria: Pfizer.
Alessandra di Pietro. Stock and Other Ownership Interests: Pfizer. Honoraria: Pfizer.
Paolo A. Ascierto. Stock and Other Ownership Interests: PrimeVAX. Consulting or Advisory Role: Bristol Myers Squibb, Roche/Genentech, MSD, Novartis, Array BioPharma,Merck Serono, Pierre Fabre, Incyte, MedImmune, AstraZeneca, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar,Boehringer Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Takis Biotech, Lunaphore Technologies, Seagen, ITeos Therapeutics, Medicenna,Bio-Al Health. Research Funding: Bristol Myers Squibb (Inst), Roche/Genentech (Inst), Array BioPharma (Inst), Sanofi (Inst). Travel, Accommodations, Expenses: MSD.
The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Writing support was provided by Blaise Low, PhD, of Nucleus Global, an Inizio company, and was funded by Pfizer.
Patient reviewers on this PLSP have received honorarium from Future Oncology for their review work but have no other relevant financial relationships to disclose.
LinkOut - more resources
Full Text Sources
Research Materials
